Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine



Contact Information for physicians and patients

Hepatology Department
CHU Paris Est – Hôpital Saint-Antoine
184 rue du Faubourg Saint-Antoine
75012 PARIS
+33 (0)1 49 28 28 36

Particular rare liver disease expertise of the centre

  • Primary biliary cholangitis (PBC)
  • Primary sclerosing cholangitis (PSC)
  • Autoimmune Hepatitis (AIH)
  • Low phospholipid-associated cholelithiasis (LPAC)
  • IgG4-related sclerosing cholangitis
  • Intrahepatic cholestasis of pregnancy
  • Benign recurrent intrahepatic cholestasis
  • Caroli Disease
  • Congenital hepatic fibrosis
  • Multiple Biliary Hamartomas
  • Choledochal cyst
  • Dubin-Johnson Syndrome
  • Rotor Syndrome

ERN Representatives

  • Olivier Chazouillères

    Coordinator of the Filfoie Health Network

  • Christophe Corpechot


    MIVB-H reference centre

ERN Team and Contact

Medical department physicians:

  • Dr Christophe Corpechot, Coordinator of the MIVB-H reference centre
  • E-mail: christophe.corpechot(at) – Secretariat: 33 (0) 1 49 28 28 36
  • Pr Olivier Chazouillères, Coordinator of the Filfoie Health Network
  • E-mail: olivier.chazouilleres(at) – Secretariat: 33 (0) 1 49 28 23 78
  • Dr Sara Lemoinne – Secretariat: 33 (0) 1 49 28 29 23

Other medical department staff:

  • Mrs Florence Gonthier-Dahan, CRMR secretary: 33 (0) 1 49 28 28 36
  • Dr Farid Gaouar, clinical research: 33 (0) 1 71 97 01 17
  • Mrs Karima Ben Belkacem, clinical research: 33 (0) 1 86 69 70 05

Centre information

Reference centre for inflammatory biliary diseases and autoimmune hepatitis, CRMIVB-H (Centre de Référence des Maladies Inflammatoires des Voies Biliaires et des Hépatites auto-immunes) is the coordination centre (CRMR) of the French national network for rare inflammatory and autoimmune liver diseases (MIVB-H). It is located within the Hepatology Department at the Saint Antoine Hospital, which is part of the Public Assistance Hospitals of Paris (AP-HP).

Accredited by the French Health Minister since 2005, the CRMIVB-H is a highly specialised centre, with recognised expertise regarding rare inflammatory and autoimmune liver diseases management, research and training. The CRMIVB-H hosts a multidisciplinary team with major expertise in rare hepatobiliary diseases, hepatology, liver transplantation and hepatobiliary surgery, hepatology intensive care, as well as related departments of anatomopathology, imaging, molecular genetics, immunology, interventional endoscopy, specialized biochemistry, epidemiology and statistical methodology.

As coordination centre, the CRMIVB-H manages the activity and the co-operative actions of the MIVB-H network. The MIVB-H network joins 31 French healthcare centres with competence in the management of rare inflammatory and autoimmune liver diseases of adults and children. The French Ministry of Health has officially accredited these care centres in 2008, as part of the national rare diseases plans (PNMRs). These national plans aim at structuring a high level of care for rare diseases and at improving the visibility of the apparatus thus established for both patients and healthcare professionals. 
In addition to the CRMIVB-H coordination centre, the MIVB-H network includes 3 constitutive reference centres (Lille, Grenoble, Villejuif), which have been accredited by the French Health Minister in 2017, and participate to the CRMR missions.
The CRMIVB-H, together with the CRMVF and the CRAVB-CG, are the French reference centres dedicated to rare liver diseases. They belong to the Filfoie rare diseases network, of which they constitute integral part. Among the 23 French rare diseases networks (Filières de Santé des Maladies Rares), created by the French Ministry of Health and Solidarity in 2015, as part of the second rare diseases plan (PNMR2), Filfoie is the network dedicated to adult and paediatric rare liver diseases. The purpose of Filfoie network is to manage and coordinate actions by bringing together reference and competence centres, diagnostic laboratories, research units, universities, educational, social and medico-social structures, and patient organisations.